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Metabolic syndrome (MetS) represents a combination of cardiometabolic risk factors, including visceral obesity, glucose
intolerance or type 2 diabetes, elevated triglycerides, reduced HDL cholesterol, and hypertension. MetS is rapidly increasing
in prevalence worldwide as a consequence of the “epidemic” obesity, with a considerable impact on the global incidence of
cardiovascular disease and type 2 diabetes. At present, there is a growing interest on the role of visceral fat accumulation in the
occurrence of MetS. In this review, the eﬀects of adipocytokines and other proinﬂammatory factors produced by fat accumulation
on the occurrence of the MetS have been also emphasized. Accordingly, the “hypoadiponectinemia” has been proposed as the most
interesting new hypothesis to explain the pathophysiology of MetS.
1.Introduction
The association of cardiometabolic risk factors known to
date as “metabolic syndrome (MetS)” was described in
the past years by several Authors. It has been called also
“Syndrome X” or “Deadly quartet visceral fat syndrome” to
attribute to the clustering (arterial hypertension and meta-
bolic risk factors) the role of a clinical entity related to
insulinresistance [1–3]. There is growing interest in MetS,
and the clustering of visceral obesity, diabetes mellitus,
hypertriglyceridemia, low levels of high-density lipoprotein-
cholesterol (HDL-C), and hypertension has been pro-
posed in several classiﬁcations (World Health Organization
(WHO) 1999, European Group for the Study of Insulin
Resistance (EGIR) 1999, National Cholesterol Education
Program’s Adult Treatment Panel III (NCEP/ATPIII] 2001),
International Diabetes Federation (IDF) 2006) [4–7]( T a b l e s
1, 2,a n d3).
Although insulin resistance has been considered a key
factor for the occurrence of MetS, the precise mechanism
by which these common metabolic and circulatory disorders
cluster in one individual and also why this pathophysio-
logical state is so atherogenic have not been fully clariﬁed.
Clinical studies on the morbidities of obesity suggest that the
extent of fat accumulation is not necessarily a determinant
of development of obesity-related diseases but that body
fat distribution is a more important factor for morbidity.
Using computed tomography scanning for the analysis of
adipose tissues, it has been clariﬁed that visceral adipose
tissue accumulation may have a major role in the occurrence
of hypertension, diabetes mellitus, hyperlipidemia, and
atherosclerotic diseases [8]. Visceral fat accumulation even
in mildly obese subjects has been shown to correlate with
the occurrence of coronary artery disease, especially in some
countries where the prevalence of massive obesity is much
lower than in western countries [9].
These data suggest that there is an increase in the risk of
chronic disease associated with a progressive increase in total
adiposity. This hypothesis is supported by several studies
following the discovery of Leptin in 1994, indicating that the
adiposetissuecannotbeconsideredasanorganthatpassively
stores excess energy but it is an endocrine organ directly2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Principal metabolic syndrome deﬁnitions.
WHO (1999) EGIR (1999) NCEP ATP III (2001)
Fasting plasma glucose
Glucose intolerance, IGT or
diabetes, and/or insulin resistance
together with two or more of the
following:
Insulin resistance (deﬁned as
hyperinsulinemia—top 25% or
fasting insulin values among the
nondiabetic population). Plus two
of the following:
3 or more of the following factors:
≥6.1mmol/L (110mg/dl) but
nondiabetic 5.6mmol/L (100mg/dl)
Blood pressure >140/90mmHg ≥140/90 mmHg or treatment ≥130/≥ 85mmHg
Triglycerides
Raised plasma triglycerides
≥1.7mmol/L (150mg/dl)
and/or
(i) 2.0mmol/L (178mg/dl) or
treatment and/or 1.7mmol/L (150mg/dl)
HDL-cholesterol Men: <0.9mmol/L (35mg/dl)
Women: <1.0mmol/L (39mg/dl)
<1.0mmol/L (39mg/dl) or
treatment
Men: <1.03mmol/L (40mg/dl)
Women: <1.29mmol/L (50mg/dl)
Obesity
Men: waist-hip ratio >0.90
Women: waist-hip ratio >0.85
and/or BMI >30Kg/2
Men: waist circumference ≥ 94cm
Women: waist circumference
≥80cm
Men: waist circumference >102cm
Women waist circumference
>88cm
Microalbuminuria
Urinary albumin excretion rate
≥ 20μg/min or albumin:
creatinine ratio ≥30mg/g
WHO:WorldHealthOrganization;EGIR:EuropeanGroupfortheStudyofInsulinResistance;NCEP/ATPIII:NationalCholesterolEducationProgram’sAdult
Treatment Panel III.
Table 2: International Diabetes Federation (IDF) metabolic syn-
drome worldwide deﬁnition (IDF, 2006).
Central obesity Waist circumference—ethnicity speciﬁc plus
any two of the following:
Raised triglycerides
≥1.7mmol/L (150mg/dl) or speciﬁc
treatment
Reduced HDL-C
<1.03mmol/L (40mg/dl in males)
<1.29mmol/L (50mg/dl) in females
or speciﬁc treatment
Raised blood
pressure
Systolic ≥130mmHg
or
Diastolic ≥85mmHg
or treatment of previously diagnosed
hypertension
Raised fasting
plasma glucose
Fasting plasma glucose ≥5.6mmol/L
(100mg/dl)
or previously diagnosed Type 2 diabetes.
If >5.6mmol/L or 100mg/dl, oral glucose
tolerance test is strongly recommended but
is not necessary to deﬁne presence of the
syndrome.
This is the ﬁrst classiﬁcation indicating central obesity as an obligatory
component of MetS.
HDL-C: High-density lipoprotein-cholesterol.
involved in the pathophysiology of the MetS and obesity-
related cardiovascular disease [10]. Accordingly, a key role
in the development of MetS has been recently attributed to
visceral obesity inducing hypoadiponectinemia [9, 11, 12].
In this paper we have reported some recent ﬁndings to
support the hypothesis that hypoadiponectinemia has to be
considered a link among visceral obesity and MetS.
Table 3: Values of waist circumference recommended by IDF
criteria, according to ethnicity.
Male Female
Europids >94 cm >80 cm
South Asians >90 cm >80 cm
Chinese >90 cm >80 cm
Japanese >85 cm >90 cm
South and Central
Americans
Use south Asian recommendations
South Saharian Africans Use European data
Eastern Mediterraneum
and Middle East
Use European data
A major issue for the IDF consensus consultation was the fact that criteria
used for central obesity in Asian and other populations could be diﬀerent
from those used in the West.
IDF: International Diabetes Federation.
2. The Adipokines
Adipose tissue participates in the regulation of a vari-
ety of homeostatic processes as an endocrine organ that
secretes many biologically active molecules such as lep-
tin, tumor necrosis factor-α (TNF-α), and plasminogen-
activator inhibitor type 1 (PAI-1), which contribute to the
development of cardiovascular disease [9, 13]. Furthermore,
some of these molecules, such as leptin, PAI-1, and adi-
ponectin, are known to contribute to the development of
hypertension [9, 13, 14](Figure 1).
The molecular mechanism of visceral fat-related disease
has been investigated by analysis of the gene-expression
proﬁle in both visceral and subcutaneous adipose tissue.
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↑IL-6
↓ Adiponectin
↑ TNFα
↑ Adipsin
(complement D)
↑ Plasminogen
activator inhibitor-1
(PAI-1)
↑ Resistin
↑ FFA
↑ Lactate
Inﬂammation
Type
2 diabetes
Hypertension
Atherogenic
dyslipidaemia
Thrombosis
Atherosclerosis
↑ Lipoprotein lipase
↑ Angiotensinogen
↑ Insulin
↑ Leptin
Visceral fat accumulation is characterized by a dysregulation in adypokines production with
decreased levels of protective adiponectin and increased levels of proinﬂammatory/proatherogenic
adipokines. This dysregulation is involved in the pathophysiology of all the components of MetS
(hypertension, diabetes, and dyslipidemia) and in the occurrence of inﬂammation, thrombosis, and
atherosclerosis. IL-6: interleukine-6; TNF α: tumor necrosis factor α ; FFA: free fatty acids.
Figure 1: Adverse cardiometabolic eﬀects of products of adipocytes (from Scaglione et al. ([12] modiﬁed)).
approximately 20% of all genes in the subcutaneous adipose
tissue encode secretory proteins and about 30% in the vis-
ceral adipose tissue. These bioactive substances are classiﬁed
as “adipokines or adipocytokines” and are subdivided into
adipokines adipose tissue speciﬁc bioactive substances (i.e.,
leptin and adiponectin) and adipokines abundantly secreted
from adipose tissue which are nonspeciﬁc for adipose tissue
(PAI-1, TNF-α, interleukins (IL), etc) [15]. Adipokines and
adipocytokines have a role both in the regulation of the
glucose and lipid metabolism, in the control of oxidative
stress, and in the maintenance of the vascular wall integrity
(Figure 1)[ 12, 14, 15].
3. Adiponectin
Adiponectin was discovered during gene-expression proﬁl-
ing of human adipose tissue conducted by the human cDNA
project. Located on chromosome 3q27, a locus for diabetes
susceptibility [16], adiponectin encodes a secretory protein
expressed exclusively in adipose tissue. Adiponectin contains
244 amino acids, a signal peptide, a collagen-like domain
at its N-terminus, and a globular domain at its C-terminus,
which shares sequence similarities with collagens X and VIII
as well as complement factor C1q. Despite the absence of
primary sequence similarity, the crystal structure of the C-
terminal globular domain resembles that of TNF-α. During
the same period, two other groups identiﬁed ACRP30 and
AdipoQ as mouse homologs of adiponectin. Adiponectin
has anti-inﬂammatory and antiatherogenic properties [14,
15]. The adiponectin receptors (adipoR1 and adipoR2) have
been cloned. AdipoR1 is expressed ubiquitously, whereas
adipoR2 is predominantly expressed in the liver, and both
are correlated positively with insulin sensitivity. The plasma
range of adiponectin in humans is 3–30 μg/ml, accounting
for 0.01% of total plasma protein [16]. Adiponectin exists in
awiderangeofmultimercomplexesin plasmaandcombines
via its collagen domain to create three major oligomeric
forms: trimers, hexamers, and a high-molecular-mass form.
A smaller form of adiponectin that includes the globular
domain cleaves proteolytically from full-length adiponectin
and exists in plasma, although in very small amounts [16,
17].
3.1. The Biological Eﬀects of Adiponectin in Experimental
Models. Data from animal models demonstrate the biolog-
ical eﬀects of adiponectin. In particular, it is able to inﬂuence
insulin sensitivity, glucose, and lipid metabolism and to
modulate blood pressure regulation and hypertensive target
organ disease [15, 16].
In addition, cell biological studies demonstrate multi-
ple antiatherogenic functions for adiponectin. When the
endothelial barrier is injured by attacking factors (oxidized
LDL, chemical substances, and mechanical stress), adi-
ponectin accumulates in the subendothelial space of vascular
walls by binding to subendothelial collagen, at which point
antiatherogenic properties of adiponectin become apparent.4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Inaddition,lowlevelsofadiponectinassociatedwithobesity,
MetS,anddiabetesfavorT-lymphocyterecruitmentandcon-
tribute to adaptive immune response during atherogenesis
in a mouse model of atherosclerosis [18]. Adiponectin also
attenuates growth-factor-induced proliferation of visceral
smooth muscle cells by the inhibition of mitogen-activated
protein kinase. It suppresses foam-cell formation by the
inhibition of the expression of scavenger receptors [19]
and protects plaque from rupture by inhibition of matrix
metalloproteinase function through the induction of IL-10-
dependent production of tissue inhibitor metalloproteinase.
In addition, adiponectin-deﬁcient mice show enhanced left
ventricular hypertrophy and increased mortality under pres-
sure overload. On the contrary, adenovirus mediated adi-
ponectin supplementation attenuates cardiac hypertrophy in
response to pressure overload [19].
3.2. The Biological Eﬀects of Adiponectin in Humans. The
ﬁrst indication that adiponectin might have a role in human
obesity derives from report of Hu et al., indicating that the
expression of adiponectin using northern blots is reduced
in the adipose tissue of obese mice and humans [20, 21].
However,dataonadiponectininhumansareincreasedbythe
introduction of an adiponectin immunoassay [22]. Accord-
ingly, plasma adiponectin levels are found higher in women
than in men and in nonobese than in obese subjects [12].
Therefore, adiponectin is the only fat protein that has
downregulation in relation to weight gain, and it is possible
thatanaccumulationofvisceralfatmightproduceinhibiting
factors for adiponectin synthesis or secretion, such as TNF-α
[23, 24].
Lower plasma levels of adiponectin are also predictive
of type 2 diabetes mellitus (DM) and are found in diabetic
subjectsandinpatientswithhypertriglyceridemia,lowHDL-
C, and hypertension [15, 16, 25] .H u m a ns u b j e c t swi t hm o r e
cardiovascular risk factors, or with MetS, would be expected
to have lower plasma adiponectin levels [26].
In this area of interest, conﬂicting evidences have
emerged about the prognostic role of adiponectin on car-
diovascular disease (CVD). In fact, antiatherogenic eﬀects of
adiponectin have also demonstrated in some clinical studies,
indicating that higher adiponectin levels are associated
with a reduced risk of acute myocardial infarction in men
[27]. Subjects with hypoadiponectinemia (plasma levels
<4μg/mL) have an increased risk of coronary heart disease
and multiple metabolic risk factors [28]. Subjects with renal
insuﬃciencyandwithhigheradiponectinlevelsarefreefrom
cardiovascular death for a longer period than those with
renal insuﬃciency and low adiponectin levels [29]. These
data are also conﬁrmed by the results of some large epi-
demiological studies [30, 31].
Onthecontrary,otherprospectivestudies[32,33]donot
report a signiﬁcant cardioprotective eﬀect of adiponectin.
Theseconﬂictingresultsraisethepossibilitythatadiponectin
may have diﬀerent prognostic implications in population at
diﬀerent risk of vascular disease.
In addition to the studies linking plasma adiponectin
levels to various human diseases, human genetic studies pro-
vide evidence of an association between lower adiponectin
levels and obesity, DM, dyslipidemia, hypertension, MetS,
insulin resistance, and coronary artery disease (CAD) [15,
18]. Interestingly, the association of the adiponectin genetic
variation with obesity, MetS, and DM has been recently
reported in a Taiwanese elderly population, suggesting the
genetic eﬀects of adiponectin inherited at birth could be
extended all the way to this later stage of life [34]. These data
suggest that in addition to hypoadiponectinemia associated
withvisceralfataccumulation,genetichypoadiponectinemia
may exhibit a clinical phenotype of MetS.
3.3. Relationship among Adiponectin, Obesity, and Insulin
Resistance. Adiponectin may be considered as the molecular
link between obesity and insulin resistance. Is hypoad-
iponectinemia the cause or the result of obesity and adipose
tissue-speciﬁc insulin resistance in humans?
Animal experiments using injection of recombinant
adiponectin proteins and the adiponectin knockout (KO)
mice clearly demonstrate that adiponectin produces eﬀects
on both body weight and insulin sensitivity in the liver and
muscle [18]. However, the severity of obesity observed in
adiponectin deﬁciency is totally outweighed by that in
leptin-deﬁcient mice (ob/ob), suggesting that leptin is the
master hormone of long-term weight regulation in animals.
Therefore, hypoadiponectinemia is not likely the main cause
of obesity and adipose tissue-speciﬁc insulin resistance. Low
adiponectin expression, on the other hand, is found in many
animal models of obesity [34].
The metabolic eﬀects of adiponectin, including lowering
glucose, enhancing fatty acid β-oxidation, and improving
insulin sensitivity, appear to be convincing and signiﬁcant.
Therefore,itisreasonabletoproposethathypoadiponectine-
mia is the result of obesity and adipose tissue-speciﬁc insulin
resistance, but it is the mediator from obesity to the insulin
resistance in the other peripheral tissues (such as liver and
muscle) and associated metabolic outcomes. Human genetic
studies clearly demonstrate that adiponectin gene variants
areoneofthecausesofobesityandinsulinresistance,usually
with an odds ratio of less than 2, which is as expected for
a polygenic disorder. Hypoadiponectinemia also does not
predict obesity in a human prospective study while it is
shown to predict the development of type 2 DM. Inter-
estingly, signiﬁcant body weight reduction in humans was
shown to raise plasma adiponectin levels accompanied with
improved insulin sensitivity [35].
The next question then is what does cause adiponectin
expression in obesity, and how does it happen? It is possible
to hypothesize that the expression of adiponectin in the
adipose tissue is inhibited by the mechanisms related to
obesity-induced insulin resistance, such as inﬂammation.
This inhibition could be reversed by weight reduction,
which improves adipose tissue-speciﬁc insulin sensitivity. In
human subjects treated with PPARγ2 agonist, the insulin
sensitizer that mainly acts in the adipose tissue increases
plasma adiponectin, by approximately twofold in spite of
a signiﬁcant body weight gain, which is almost routinely
seen in this kind of treatment [36]. These ﬁndings indicated
that improving adipose-speciﬁc insulin sensitivity is ableJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Importance of visceral fat accumulation and hypoadiponectinemia in the occurrence and progression of
MetS.
Increased visceral obesity is characterized by dysregulated adipokine production, with decrease in anti-
inﬂammatory/atheroprotective adipokines (adiponectin) and increase in proinﬂammatory/atherogenic
adipokines (TNF-α, IL-6, etc.). These adipokines participate together insulin resistance to the occurrence of
MetS and atherosclerotic cardiovascular diseases.
Increase in TNF-α, IL-6, etc.
Premetabolic syndrome
Figure 2: Progression and outcomes of visceral obesity.
to increase adiponectin gene expression irrespective of the
changes in adiposity.
Therefore, adipose tissue-speciﬁc insulin sensitivity rath-
er than general adiposity itself determines the adiponectin
expression in adipose tissues. Secondary to the increased
plasmaadiponectin,thewholebodyinsulinsensitivitywould
be expected to improve.
The molecular mechanisms of obesity-induced adipose
tissue-speciﬁc insulin resistance may be elucidated by study-
ing the molecular regulation of adiponectin gene expression.
3.4. Relationship among Adiponectin, Hypertension, and
Insulin Resistance. Furuhashi et al. [37] reported that only
hypertensive patients with insulin resistance showed a de-
creased adiponectin concentration. However, the cause-ef-
fect relationship among hypoadiponectinemia, insulin resis-
tance, and hypertension has not been clearly elucidated.
Even though the consensus has been that insulin resis-
tance is correlated with hypertension, [38] the association
between insulin and hypertension is controversial [39]. In
fact, homeostasis model assessment (HOMA) index was not
signiﬁcantly diﬀerent between hypertensive and normoten-
sive subjects in some studies, but, as a speciﬁc ﬁnding,
plasma adiponectin level signiﬁcantly decreased with an
increase in blood pressure, even in the normotensives
without insulin resistance or diabetes [13, 40, 41]. These
results indicate that hypoadiponectinemia may aﬀect the
pathogenesis of hypertension at a very early stage without
involving insulin resistance. In addition, Lindsay et al. [42]
reported that there were loci on chromosomes 2, 3, 9,
and 10 aﬀecting the circulating adiponectin concentration
in the Pima Indian population, suggesting the possibility
of an unknown modulator of adiponectin level. However,
further data are required to support this hypothesis. There
are 4 possible reasons for the negative correlation between
hypertension and plasma adiponectin concentration. First,
plasma adiponectin concentration was independently corre-
lated with the vasodilator response to reactive hyperemia, so
adiponectin concentration could be an independent param-
eter of endothelial function. Endothelial dysfunction is an
important feature of the early stage of atherosclerosis, which
is related to pathogenic conditions including hyperten-
sion [43]. Furthermore, in adiponectin-KO mice, hypoad-
iponectinemia causes diet-induced hypertension. Second, an
increase in sympathetic nerve activity, which is common
in hypertensives, may inhibit adiponectin gene expression
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association of adiponectin and high-sensitive C-reactive
proteinorincreasedriskofarteriosclerosissuggeststhatalow
adiponectin concentrationmightenhancethepredisposition
to hypertension via vascular injury [13]. Fourth, activation
of the renin-angiotensin system may be induced in adipose
tissuebyhypoadiponectinemia,resultinginanincreaseinfat
mass and blood pressure [45].
4. Conclusions
Although risks that cluster in MetS are common, it is
likely that the cluster occurs coincidentally. Adiponectin
is a unique and essential adipocytokine that is produced
very abundantly in adipocytes and stably present in the
plasma at very high concentration. In healthy subjects,
adiponectin carries out its roles for preventing development
of vascular changes and the impairment of glucose and lipid
metabolism, which may be induced by a variety of attacking
factors, such as chemical substances, mechanical stress, or
nutritional loading, like a ﬁreﬁghter who is putting out
small ﬁres to keep them from becoming big. Studies on the
genetic mutation of adiponectin gene in human subjects
and the KO mice clearly demonstrate that adiponectin may
play a key role also in the prevention of MetS [8, 17,
24, 46]. Acquired hypoadiponectinemia observed in obesity,
especially with visceral fat accumulation, and hypertension,
is much more frequent than genetic hypoadiponectinemia.
Hypoadiponectinemia together with the increase of other
adipocytokines(i.e.,TNF-alfaorPAI-1)inducedbytheaccu-
mulation of visceral obesity might be a major background
of vascular changes as well as metabolic disorders, including
insulin resistance, which are the characteristics of so-called
“metabolic syndrome” (Figure 2).
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